Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jazz Pharmaceuticals (JAZZ) PT Cut to $170 at Canaccord Genuity
November 10, 2015 10:20 AM ESTJazz reported a slightly disappointing Q3 with revenue of $340.9M, missing consensus by $7M. Non-GAAP EPS for the Q was $2.52, below consensus of $2.56.
Full-year guidance was narrowed slightly but it's more toward the lower end of the range given in Q2. Canaccord Genuity analyst, Corey Davis, noted that... More
Delays at the central pharmacy Negatively Hit Jazz Pharmaceuticals (JAZZ); Piper Jaffray Cuts Price Target to $186
November 10, 2015 9:51 AM ESTPiper Jaffray reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $186.00 (from $208.00), following the company's 3Q earnings report. Jazz reported non-GAAP EPS of $2.52 on revenues of $341M, largely in-line with the Street estimates of $2.56 and $348M, respectively. Xyrem sales totaled $243M, up from $204M in 3Q14, with annual volume... More
Mizuho Securities Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral
November 10, 2015 6:31 AM ESTMizuho Securities downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Outperform to Neutral with a price target of $140.00 (from $164.00) on valuation.
Analyst Irina Koffler commented, "We are downgrading Jazz to NEUTRAL from BUY and lowering our PT from $164 to $140 on revised valuation methodology.... More
After-Hours Stock Movers 11/09: (BLCM) (MDR) (RAX) Higher; (LF) (SGMS) (LGF) (GPS) Lower (more...)
November 9, 2015 6:09 PM ESTLeapFrog Enterprises (NYSE: LF) 23.7% LOWER; reported Q2 EPS of ($0.48), $0.29 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $67.2 million versus the consensus estimate of $88.49 million. The Company's updated outlook for fiscal year 2016 is for net sales to contract considerably relative to the prior year, and operating losses, excluding goodwill and impairments to be greater than fiscal year 2015... More
Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
November 9, 2015 4:10 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.
Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015... More
Trading Radar for 11/9: DISH Network (DISH), WhiteWave Foods (WWAV), Caesars (CZR), Plug Power (PLUG), Arch Coal (ACI) Report
November 6, 2015 2:39 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
Affiliated Managers Group (NYSE: AMG) - consensus EPS $2.87
Alnylam Pharma (Nasdaq: ALNY) - consensus loss $0.91
Altisource Residential (Nasdaq: RESI) - consensus EPS $0.39
Arch Coal (NYSE: ACI) - consensus loss $5.45
Atento S.A. (NYSE: ATTO) - consensus EPS $0.37
Avino Silver & Gold Mines (NYSE: ASM)... More
